238 related articles for article (PubMed ID: 16409461)
1. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.
Eriksson BI; Borris L; Dahl OE; Haas S; Huisman MV; Kakkar AK; Misselwitz F; Kälebo P;
J Thromb Haemost; 2006 Jan; 4(1):121-8. PubMed ID: 16409461
[TBL] [Abstract][Full Text] [Related]
2. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.
Turpie AG; Fisher WD; Bauer KA; Kwong LM; Irwin MW; Kälebo P; Misselwitz F; Gent M;
J Thromb Haemost; 2005 Nov; 3(11):2479-86. PubMed ID: 16241946
[TBL] [Abstract][Full Text] [Related]
3. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
Fisher WD; Eriksson BI; Bauer KA; Borris L; Dahl OE; Gent M; Haas S; Homering M; Huisman MV; Kakkar AK; Kälebo P; Kwong LM; Misselwitz F; Turpie AG
Thromb Haemost; 2007 Jun; 97(6):931-7. PubMed ID: 17549294
[TBL] [Abstract][Full Text] [Related]
5. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Misselwitz F; Muehlhofer E; Kälebo P
Thromb Res; 2007; 120(5):685-93. PubMed ID: 17292948
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
[TBL] [Abstract][Full Text] [Related]
7. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Lassen MR; Mouret P; Rosencher N; Kälebo P; Panfilov S; Eskilson C; Andersson M; Freij A;
J Thromb Haemost; 2003 Dec; 1(12):2490-6. PubMed ID: 14675083
[TBL] [Abstract][Full Text] [Related]
8. Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.
Sindali K; Rose B; Soueid H; Jeer P; Saran D; Shrivastava R
Eur J Orthop Surg Traumatol; 2013 May; 23(4):481-6. PubMed ID: 23412293
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement.
Agnelli G; Haas S; Ginsberg JS; Krueger KA; Dmitrienko A; Brandt JT
J Thromb Haemost; 2007 Apr; 5(4):746-53. PubMed ID: 17408408
[TBL] [Abstract][Full Text] [Related]
10. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
Weitz JI; Bauersachs R; Becker B; Berkowitz SD; Freitas MCS; Lassen MR; Metzig C; Raskob GE
JAMA; 2020 Jan; 323(2):130-139. PubMed ID: 31935028
[TBL] [Abstract][Full Text] [Related]
11. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
Weitz JI; Cao C; Eriksson BI; Fisher W; Kupfer S; Raskob G; Spaeder J; Turpie AG
Thromb Haemost; 2010 Dec; 104(6):1150-7. PubMed ID: 20886185
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
[TBL] [Abstract][Full Text] [Related]
13. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Mouret P; Rosencher N; Eskilson C; Nylander I; Frison L; Ogren M;
Thromb Haemost; 2003 Feb; 89(2):288-96. PubMed ID: 12574809
[TBL] [Abstract][Full Text] [Related]
14. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
Kakkar AK; Brenner B; Dahl OE; Eriksson BI; Mouret P; Muntz J; Soglian AG; Pap AF; Misselwitz F; Haas S;
Lancet; 2008 Jul; 372(9632):31-9. PubMed ID: 18582928
[TBL] [Abstract][Full Text] [Related]
15. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
[TBL] [Abstract][Full Text] [Related]
16. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.
Turpie AG; Gallus AS; Hoek JA;
N Engl J Med; 2001 Mar; 344(9):619-25. PubMed ID: 11228275
[TBL] [Abstract][Full Text] [Related]
17. SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study.
Lassen MR; Dahl O; Mismetti P; Zielske D; Turpie AG
J Am Coll Cardiol; 2008 Apr; 51(15):1498-504. PubMed ID: 18402906
[TBL] [Abstract][Full Text] [Related]
18. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2).
Eriksson BI; Turpie AG; Lassen MR; Prins MH; Agnelli G; Kälebo P; Wetherill G; Wilpshaar JW; Meems L;
J Thromb Haemost; 2010 Apr; 8(4):714-21. PubMed ID: 20088935
[TBL] [Abstract][Full Text] [Related]
19. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.
Van Thiel D; Kalodiki E; Wahi R; Litinas E; Haque W; Rao G
Clin Appl Thromb Hemost; 2009; 15(4):389-94. PubMed ID: 19608550
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Turpie AG; Lassen MR; Davidson BL; Bauer KA; Gent M; Kwong LM; Cushner FD; Lotke PA; Berkowitz SD; Bandel TJ; Benson A; Misselwitz F; Fisher WD;
Lancet; 2009 May; 373(9676):1673-80. PubMed ID: 19411100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
